
    
      Study participants with the following mild to moderate per protocol defined co-morbidities
      will be recruited: chronic kidney disease (CKD); cardiovascular disease (CVD), chronic
      obstructive pulmonary disease (COPD), type-2-diabetes. After safety data review, recruitment
      for severe cases will be opened. No severity classification will be done for study
      participants with chronic human immunodeficiency virus (HIV) infection with stable viremia 12
      months prior enrollment, for renal transplant patients if stable under medication for at
      least 6 months prior enrollment, and for study participants with a body mass index > 32
      kg/m^2.
    
  